Developing a practical means of reducing alloimmunization in chronically transfused patients would be of significant clinical benefit. Immunocamouflaging red blood cells (RBCs) by membrane grafting of methoxypoly(ethylene glycol) (mPEG) may reduce the risk of allo-immunization. The results of this study showed that antibody recognition of non-ABO antigens was significantly reduced in an mPEG-dose-and polymer size-dependent manner, with higher molecular weight mPEGs providing better immunoprotection. Furthermore, in vivo immunogenicity was significantly reduced in mice serially transfused with mPEG-modified xenogeneic (sheep; sRBCs), allogeneic (C57Bl/6), or syngeneic (Balb/c) RBCs. Following a primary transfusion of sRBCs, mice receiving mPEG-sRBCs showed a >90% reduction in anti-sRBC IgG antibody levels. After two transfusions, mice receiving mPEG-sRBCs showed reductions of >80% in anti-sRBC IgG levels. Importantly, mPEG-modified autologous cells did not induce neoantigens or an immune (IgG or IgM) response. These data suggest that the global immunocamouflage of RBCs by polymer grafting may provide a safe and cost-effective means of reducing the risk of alloimmunization. Safe and effective blood transfusions are arguably one of the most important medical advances made in the past century. These procedures are now common place and have saved millions of lives; however, until recently, this process has been of only limited interest to the research community.
Safe and effective blood transfusions are arguably one of the most important medical advances made in the past century. These procedures are now common place and have saved millions of lives; however, until recently, this process has been of only limited interest to the research community. There is a substantial body of evidence showing that clinical problems can occur in chronically transfused patients because of alloimmunization [1] [2] [3] . These problems are compounded by the fact that it is difficult, time-consuming and expensive to phenotype blood cells for mismatched antigens at non-ABO/RhD epitopes. Yet these mismatches can, and do, have a significant impact on patient care--especially for chronically transfused sickle cell and thalassemic patients. Indeed, by some estimates, up to 35% of sickle patients show clinically significant levels of alloimmunization (i.e., shortened RBC survival and mild fever) to non-ABO/RhD antigens [4, 5] . Of these alloimmunized patients, some become so reactive to donor RBCs that even the most closely matched samples cause a transfusion reaction, thus endangering the life of the patient.
To address the problem of donor RBC alloimmunization, several clinical approaches have been suggested. These interventions range from minimal preventative action (addressing the problems of alloimmunization only after it occurs) to extensive prescreening of donor and recipient blood for the antigens most commonly associated with an increased risk of alloimmunization [6, 7] . This latter approach has been criticized because the screening process is expensive and alloimmunization typically requires repeated antigen exposure [8] . While this argument has economic merit, it is akin to not screening donor blood for transmissible disease and only treating the patient after they have been infected. Therefore, the development of a cost-effective and practical means of reducing the risk of alloimmunization to all/most RBC alloantigens would be of significant clinical benefit.
Ongoing work on the covalent modification of RBC and other blood cells with methoxypoly(ethylene glycol) (mPEG; PEGylation) suggests that polymer grafting may prove to be a practical prophylactic method of decreasing the risk of transfusional alloimmunization and a treatment for patients that have already been alloimmunized [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . To further examine the potential clinical application of "immunocamouflaged" erythrocytes, the effects of polymer size on the antigenic recognition of non-ABO blood group antigens expressed by normal human RBCs was investigated. Also, the immunocamouflage and immunogenic potential of unmodified and PEGylated syngeneic, allogeneic and xenogeneic RBCs were examined in a murine transfusion model.
Materials and methods

RBCs and human sera
After obtaining informed consent, whole venous blood was drawn from normal healthy volunteers into heparin-containing Vacutainer tubes. To prevent storage artifacts, all samples were processed immediately. Care was taken to ensure adequate representation of males and females, and no individuals were excluded on the basis of race or gender. Erythrocytes were washed three times in isotonic saline prior to use. Serum was prepared from venous blood collected in serum separator tubes (SST Vacutainer tubes; Becton Dickinson, Fairview, NJ, USA) and stored at −70°C. All biochemicals (unless stated otherwise) were obtained from Sigma Chemical Co. (St. Louis, MO, USA).
Preparation of PEG-modified RBCs
To assess the effect of molecular weight on the immunocamouflage of blood group antigens and intact RBCs, monofunctional (i.e., one binding site per chain) activated mPEGs of 2-30 kD were examined. Cyanuric chloride-activated mPEG (C-mPEG; 5 kD) and unactivated, soluble, mPEG (sol-mPEG; 5 kD) were obtained from Sigma. Methoxypoly(ethylene glycol)-benzotriazolyl carbonate (BTC-mPEG; 5 and 20 kD) was obtained from Nektar Therapeutics (San Carlos, CA, USA). Succinimidyl valerate methoxypoly(ethylene glycol) (SVA-mPEG; 2, 5, 20 and 30 kD) was obtained from Laysan Bio Inc. (Arab, AL, USA). In addition, fluorescein-SVA-mPEG (fluor-SVA-mPEG; Laysan Bio Inc.) was used to visualize the homogeneity of polymer grafting.
Washed human erythrocytes were covalently grafted with activated mPEGs as previously described [9] [10] [11] 14] . Stock solutions of PEG-derivatives were made in PEG-buffer (50 mmol L −1 dibasic potassium phosphate, 105 mmol L −1
NaCl, pH 8.0) and mixed with washed human erythrocytes (12% final hematocrit) using a micromixing device to assure homogeneous modification. Derivatization reactions were carried out at room temperature for 30 min or, in some cases, 60 min. Modified RBCs were then washed three times with phosphate buffered saline (PBS). A control group comprising RBC incubated in mPEG-free PEG-buffer (0 mmol L −1 mPEG-RBC) was used to determine the effects of blood processing on immune complex binding. RBCs incubated with sol-mPEG (i.e., incapable of membrane grafting) were included as an additional control.
Two-phase partitioning
Partitioning of control and PEG-modified RBCs was carried out in an aqueous two-phase system comprising PEG8000 (Sigma) and Dextran T500 (molecular weight ~500000; Sigma) as previously described [13] . The concentrations of the PEG and Dextran stock solutions were determined by refractive index measurements. Control or modified RBCs were added to 1 mL of PEG8000 and mixed. An aliquot (0.5 mL) of the PEG-RBC mixture was then overlaid on 0.5 mL of Dextran T500 and mixed. The two-phase system was allowed to separate at room temperature for 20 min prior to quantitation of the RBCs (via hemoglobin concentration) in the PEG layer. The results were expressed as the percentage of total hemoglobin in the upper PEG phase and were representative of a minimum of three independent experiments.
Anti-A/B antibody mediated RBC agglutination
The effect of grafted polymers on anti-sera-mediated RBC agglutination was assessed using a modified platelet aggregometer assay as previously described [9, 10] . This assay allows the highly reproducible quantitation of the effects of PEGylation on anti-sera-mediated agglutination. Briefly, 450 μL of control or PEGylated RBC (blood type A) suspension (6% hematocrit in isotonic saline) were placed in an aggregometer cuvette at 37°C with stirring. Anti-A typing serum (or pooled human antiserum; 20 μL) was added and RBC aggregation was monitored over time.
Detection of blood group antigens by flow cytometry
Blood typing antibodies, unless otherwise noted, were purchased from Immucor, Inc. (Norcross, GA, USA). To quantitate the degree of immunocamouflage induced by the grafted polymers, flow cytometry (FACSCalibur; BD Biosciences San Jose, CA, USA) was performed using previously established erythrocyte parameters [12] [13] [14] . A minimum of 20000 cells was analyzed per sample. Control and PEG-modified RBCs were diluted to a 3% hematocrit in isotonic saline and resuspended in an equal volume of a specific anti-RBC antibody. The RBC-antibody mixtures were then incubated for 30 min at 37°C followed by washing twice with saline. A fluorescein isothiocyanate (FITC)-conjugated anti-human IgG-Fc specific secondary antibody (Sigma; 50 μL; diluted 1 : 50 in saline) was added to each sample tube and the mixtures incubated at 37°C for 30 min. The RBCs were washed twice in saline and fixed in 1% methanol-free formaldehyde (MFF). Immunocamouflage of blood group antigens was assessed using both Percent Gated and Mean Cell Fluorescence (MCF).
In vivo RBC survival studies
To examine the effects of the various mPEG derivatives in vivo, RBC survival studies were performed in Balb/c mice [9, 12, 13] . All animal studies were institutionally approved and conducted in compliance with all applicable Canadian animal care regulations. RBCs were collected from donor mice via cardiac puncture and derivatized with SVA-mPEG (20 kD) as previously described. The concentration of mPEG used for the in vivo studies ranged from 0 to 2 mmol L −1
, since murine RBCs are physically smaller (i.e., have fewer surface binding sites for mPEG) and more fragile than human RBCs. Murine RBCs were labeled using the fluorescent membrane anchored marker, PKH-26 (Sigma). Blood samples from recipient mice were monitored until the labeled RBC was cleared from the circulation (approximately 50 d for unmodified syngeneic cells). Survival of fluorescently labeled mPEG-treated and control RBCs was monitored by analyzing the percentage of fluorescently-labeled RBCs in the peripheral circulation by flow cytometry. A minimum of five mice was used per mPEG concentration tested.
In vivo RBC immunogenicity
For in vivo immunogenicity studies, two genetically distinct mouse strains (C57Bl6 and Balb/c; H-2K b and H-2K d ) were used to assess alloimmunization [21, 22] . Donor RBCs were obtained from C57/Black or Balb/c mice by cardiac puncture. To further assess the immunomodulatory effect of PEGylation, sheep RBCs were obtained from Cocalico (Reamstown, PA, USA). Mouse and sheep RBCs were washed three times in isotonic saline, and resuspended at a final concentration of 5 g% (~12% hematocrit). The RBC suspension was derivatized with C-mPEG at concentrations of 0, 1.2 and 5 mmol L −1 for 30 min at 4°C in PBS (pH 9.2).
After derivatization, the cells were washed three times in isotonic saline and resuspended to a 50% hematocrit prior to transfusion. Recipient mice (Balb/c; n=24) were transfused intraperitoneally (i.p.) with 500 μL of control or mPEG-modified C57Bl/6 or Balb/c RBCs. This procedure was repeated for up to three transfusions (each at ~50 d intervals). At the end of each transfusion, eight mice per group were sacrificed and serum was collected for analysis of anti-donor antibody formation. Sera from four mice were pooled, while the remaining four mice were analyzed separately (to assess response variation) for IgG and IgM antibodies against the transfused RBCs. Antibody binding was quantitated by mixing 600 μL of serum with saline (at ratios of 2 : 1, 1 : 1, and 1 : 5) with 200 μL of an 80% hematocrit of unmodified donor RBCs. The samples were mixed for 30 min at 37°C and then washed three times in isotonic saline. Secondary antibodies to mouse IgG (PE labeled) and IgM (FITC-labeled) were added to 20 μL of the previously incubated packed RBCs and mixed for 30 min at 37°C followed by washing three times in isotonic saline. Secondary antibody binding was quantitated by flow cytometry as described above.
The immunogenicity of control and PEGylated xenogeneic sheep RBC was similarly assessed in Balb/c mice. Mouse serum was collected 14 d after the primary transfusion of sheep RBCs and the presence of mouse anti-sheep RBC IgG and IgM was assessed by flow cytometry. In addition, some mice received a second transfusion of sheep cells (14 d after the primary transfusion) and serum was collected 28 days post-primary transfusion and assessed for anti-sheep IgG and IgM. Mice were transfused with a blood volume approximating 10% of the total mouse blood volume and each group contained a minimum of eight mice.
Statistical analysis
All results were expressed as the mean±standard error of the mean (SEM) unless otherwise stated. Each experiment was repeated a minimum of three times although, in some cases (e.g., microscopy), representative samples are presented. Statistical analysis was performed using SPSS v.16.0 statistical software (SPSS Inc., Chicago, IL, USA). One-way analysis of variance (ANOVA) followed by Tukey's posthoc test was performed for comparison of three or more mean values. An independent variable t-test was used for comparison of two mean values. A two-tailed P-value<0.05 was considered significant.
Results
Biophysically, membrane grafted polymers alter the surface characteristics of cells as denoted by changes in separation profiles in a two-phase (Dextran-PEG) partitioning system. As shown in Figure 1A , the biophysical partitioning of modified RBCs is dependent upon both grafting concentration and polymer size. However, large polymers more effectively shifted the modified RBCs into the PEG layer, even at very low grafting concentrations. As shown, grafting of the 2 kD polymer only resulted in significant partitioning of the RBCs to the PEG layer at higher grafting concentrations. By contrast, the 20 and 30 kD SVA-mPEG modified RBCs rapidly moved into the PEG layer, even at very low grafting concentrations, with maximal partitioning occurring at ≥0.5 mmol L Figure 1B ). Importantly, linker chemistry (as shown by the 5 kD C-and SVA-mPEG) was not a significant factor in phase separation as long as the linker chemistries showed similar reactivity and hydrolysis rates.
Polymer length was also important in preventing antigenic recognition of the A/B antigens on RBCs. As shown in Figure 2 , polymer lengths of 2, 5 and 20 kD all conferred some degree of protection against antisera-mediated agglutination of type A RBCs. This protection against antibodymediated agglutination was both size-and dose-dependent, with long chain polymers providing significantly better inhibition of agglutination (Figure 2A-C) . This finding correlates well with the observed partitioning of RBCs in the PEG-Dextran two-phase system. As noted in Figure 2C , grafting concentrations ≥1.2 mmol L −1 of the 20 kD polymer resulted in the complete loss of anti-A-mediated agglutination. Grafting efficacy was also highly malleable in terms of both pH and the grafting time of the PEGylation reaction ( Figure 2D ). No statistically significant difference was observed between pH 8.0 and 9.2 after either 30 or 60 min of derivatization (2.5 mmol L −1 5 kD SPA-mPEG). Similarly, while a 60-min grafting reaction appeared to confer some advantages in terms of inhibiting anti-A agglutination, this observed difference (2.5 mmol L −1 5 kD SPA-mPEG) was not significant when the effect of time was assessed using the control cells (0 mmol L −1 SPA-mPEG).
While immunocamouflage of A/B antigens was observed, it was not sufficient to yield a true "universal erythrocyte" as the method cannot remove all risk from an untyped blood recipient. However, immunocamouflage of the non-ABO blood group antigens holds much greater clinical potential. The Rhesus blood group antigens, especially RhD, are particularly important in transfusion medicine. As shown in Figure 3 , RhD, Rhc, and RhE are all effectively camouflaged by grafted mPEG. Immunocamouflage of the D, c, and E antigens is dependent upon both grafting concentration and polymer size. Immunocamouflage of antigenic epitopes is shown by the absolute camouflage (Percent While in vitro assays demonstrate the efficacy and potential clinical value of immunocamouflaged RBCs, in vivo efficacy and stability are both crucial for evaluating potential utility. Importantly, immunocamouflage of RBCs did not adversely affect in vivo survival in a murine transfusion model. Figure 5A shows both the mean clearance curves for PKH-26-labeled control and polymer-modified (2 mmol L −1 BTC-mPEG) RBCs and the clearance curves of the individual mice (n=5 per group). As noted, no significant differences were observed between the groups and both populations fell within normal murine clearance patterns. Furthermore, Figure 5B shows that immunocamouflage of syngeneic donor cells did not induce the formation of neoantigens, or expose cryptoantigens, which would have resulted in immune recognition and clearance by the recipient mice. This was demonstrated by a lack of IgG (shown) and IgM (not shown) antibody production to either the control or mPEG-RBCs over the course of 1-3 transfusions (up to ~180 d). More importantly, with regards to the potential clinical utility of immunocamouflaged RBC, polymer modified allogeneic (C57Bl/6 into Balb/c) RBCs showed a highly significant (P<0.001) blunting of antibody production relative to the unmodified allogeneic donor cells ( Figure 5C ). This effect remained potent after three transfusions with modified allogeneic donor RBCs (~180 d). In contrast to mPEG-RBCs, unmodified allogeneic RBCs induced a sig- nificant antibody response, though it should be noted that these antibodies did not significantly affect donor cell circulation time. The immunocamouflaging effect of the grafted polymers also provided a potent (P<0.001) immunoprotective effect on xenogeneic (sheep) RBCs ( Figure  5D ).
Discussion
Despite ABO/RhD matching, the RBC remains an antigenically challenged cell. Adverse reactions, ranging from clinically insignificant to significant, arising from non-ABO/RhD antigens are relatively common, due in large part to varying expression of these epitopes by different ethnic and racial groups [4, 23] . Indeed, transfusion reactions arising from the non-ABO/RhD blood group antigens are most commonly encountered in minority populations. Coupled with this is the finding that the incidence of alloimmunization is also positively correlated with the number of transfusions an individual receives. Hence, alloimmunization to non-ABO/ RhD blood group antigens is exaggerated in certain individuals, especially minorities, with chronic diseases (e.g., sickle cell disease or thalassemia) receiving transfusion therapy [1, 4, 24] . Consequent to alloimmunization, transfusion reactions against non-ABO/RhD RBC antigens can make it almost impossible to identify appropriate blood donors [25] . To prevent the risk of extreme alloimmunization, various clinical interventions have been explored. These include the now standard use of packed RBCs in place of whole blood (to prevent alloimmunization due to white blood cells), extensive pre-transfusion phenotype screening to more closely match donor and patient RBCs, and the long-term use of single RBC donors. Despite these often costly measures, clinically significant alloimmunization rates can still exceed 30% in patients with sickle cell anemia and thalassemia [26] . Consequently, many laboratories and clinicians question the cost effectiveness of donor screening as a prophylactic measure to prevent alloimmunization.
Hence, a cost effective means of diminishing/preventing the risk of alloimmunization is urgently needed. To this end, immunocamouflaged RBCs may prove to be of clinical value [20] . As shown in the present study, immunocamouflaged RBCs are characterized by global camouflage of the ABO and non-ABO human blood group antigens ( Figures  2-4) and a significant attenuation of donor cell immunogenicity ( Figure 5 ) in a murine transfusion model. This is effectively accomplished at dosages that do not adversely affect the in vitro or in vivo stability and function of human or murine RBCs. In addition, the procedure is inexpensive and can be readily adapted to existing blood banking technology.
While the moderate derivatization concentrations (≤2.5 mmol L −1 mPEG per 0.6×10 9 RBC mL −1 ) that are likely to be used for human RBC do not completely camouflage the A/B blood group antigens, these grafting concentrations do result in significant masking of clinically relevant non-ABO antigens. Importantly, it is not necessary to achieve a state of complete immunocamouflage to significantly reduce the risk of alloimmunization due to these non-ABO blood groups. As shown in Table 1 , the observed risk of alloimmunization is governed, in part, by the number of cells positive for a particular antigen, the apparent antigen density of the antigen on the cell, and the ability of appropriate antigen presenting cells to recognize, phagocytose and present that antigen. PEGylation of donor RBCs dramatically reduces the efficiency of each of these steps: The number of [27] . The antigenic sites are presented as ranges because the number expressed is dependent upon the absence or presence of other antigens. *, percentage of null recipients sensitized after a single transfusion. Ac, acute transfusion reaction. **, from Hughes-Jones et al. [28] ; ***, from Masouredis et al. [29] ; #, from Skov [30] .
antigen positive cells is reduced, the apparent antigen density on the positive cells is decreased, PEGylated cells are less effectively phagocytosed, and antigen presentation of PEGylated proteins is impaired [9, [20] [21] [22] 31] .
The net result of these events on clinical practice may be illustrated by examining the potential effects that immunocamouflaged RBCs may have on the risk of alloimmunization to Rhc. Table 1 shows that 'clinical experiments' (i.e., unintentional mismatches at specific antigens) determine the relative risk of immunogenic recognition for Rhc to be approximately 2% after a single mismatch [28] [29] [30] . As noted in Figure 3 , Rhc is readily camouflaged by mPEG-grafting, as shown by a decrease in both percent positive cells and MCF. This finding raises the question: What would be the residual alloimmunization risk of Rhc + donor RBCs subsequent to polymer grafting (e.g., 2.5 mmol L −1 of a 20 kD polymer)? Our in vivo murine data ( Figure 5 ) with allogeneic and xenogeneic donor cells suggests that the actual risk of alloimmunization would be significantly reduced. Hence, the 2% risk of immunogenic recognition may subsequently become a 0.2 or a 0.02% risk of alloimmunization. Thus, while some individuals will become alloimmunized, even after receiving PEGylated blood, the relative risk to an individual, and to the chronically transfused patient population as a whole, will be dramatically reduced. Indeed, mPEG-RBCs (syngeneic, allogeneic and xenogeneic) show decreased immunogenicity. A number of studies show that, while PEG has low immunogenic potential, it does (under some circumstances) induce anti-PEG antibodies [32] [33] [34] [35] . Typically, in animal models this has required the co-administration of Freund's Complete Adjuvant or coupling of PEG to highly immunogenic proteins [32, 33] . More recently, studies have reported that a significant percentage of normal blood donors show evidence of anti-PEG antibodies [34, 35] . However, most long-term studies on PEGylated human enzymes have failed to report any significant anti-PEG effects. Moreover, no antibody response (either IgG or IgM) was noted in response to donor syngeneic mPEG-RBC in the murine transfusion model used in the present study. Indeed, repeated transfusion of syngeneic mPEG-RBCs showed no increased clearance in our murine model. More importantly, highly immunogenic allogeneic and xenogeneic cells demonstrated significantly decreased murine antibody responses in recipient mice.
In summary, global camouflage of RBC antigens by methoxypoly(ethylene glycol) derivatization dramatically attenuates both recognition of blood group antigens and the in vivo immunogenicity of antigenically disparate cells. Immunocamouflage arises from the biophysical effects of the grafting polymer, which both attenuates cell surface charge (hindering receptor-ligand interactions) and sterically impedes the approach and binding of antibodies and/or cells [20, 36] . These data clearly suggest that PEGylation of non-ABO/RhD matched RBCs effectively reduces the risk of alloimmunization in chronically transfused patients. Application of this technology may be clinically useful in chronically transfused sickle and thalassemic patients because of the increased risk of alloimmunization faced by these patient populations.
